The clinical hold and trial termination eliminate near-term catalysts. Monitor for FDA resolution or partnership/licensing for ARD-101, but with no pipeline catalysts and ongoing cash burn, the stock faces continued downside risk. The cash runway into late 2027 provides some buffer but no value inflection without clinical progress.
Price Chart
Executive Summary
Aardvark Therapeutics reported Q2 2026 EPS of -$0.66, a 12.3% miss vs consensus of -$0.88, with zero revenue. The company terminated its Phase 3 HERO and OLE trials for ARD-101 in PWS and remains under FDA clinical hold. Cash burn continues with $73.9M remaining, funding operations into late 2027, but the pipeline is stalled with no clear path forward.
Key Financial Metrics
Key Facts
- Q2 2026 EPS -$0.66 vs consensus -$0.88 (12.3% miss)
- Zero revenue; pre-revenue clinical-stage biotech
- Phase 3 HERO and OLE trials for ARD-101 terminated in June 2026
- FDA full clinical hold on ARD-101 IND since May 2026
- Cash, cash equivalents and short-term investments $73.9M as of June 30, 2026, down from $91.2M on March 31, 2026
- Cash runway into late 2027
- R&D expenses $10.5M vs $13.1M YoY; G&A $4.6M vs $2.7M YoY
- Net loss $14.4M for Q2 2026, flat YoY
- Workforce reduction implemented in June 2026
Financial Impact
Net loss of $14.4M for Q2 2026; cash burn of ~$17.3M from Q1 to Q2 2026; $73.9M cash runway into late 2027
Risk Factors
- FDA clinical hold may not be resolved, ending ARD-101 program
- No pipeline diversification; single-asset risk
- Cash burn without revenue; potential for dilutive financing
- Workforce reduction signals cost-cutting but also program de-prioritization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3343202 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | 8-K | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 22, 2026 4d ago | Press Release | $1.39 $1.08 | ▼ −22.30% | ▼ −23.01% | $1.08 (−22.30%) |
Oct 8, 2026 18d ago | 3 | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Oct 8, 2026 18d ago | 8-K | $4.76 $4.45 | ▼ −6.51% | ▼ −6.45% | $1.08 (−77.31%) |
Aug 12, 2026 10w ago | Institutional Cluster | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | 8-K | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Aug 11, 2026 10w ago | Press Release | $6.57 $6.41 | ▲ +2.44% | ▲ +3.13% | $1.08 (+83.56%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.64 $3.90 | ▲ +7.14% | ▲ +6.60% | $1.08 (−70.33%) |
May 14, 2026 23w ago | Press Release | $4.57 $4.36 | ▲ +4.60% | ▲ +4.53% | $1.08 (+76.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers